Moinzadeh, Pia and Riemekasten, Gabriela and Siegert, Elise and Fierlbeck, Gerhard and Henes, Joerg and Blank, Norbert and Melchers, Inga and Mueller-Ladner, Ulf and Frerix, Marc and Kreuter, Alexander and Tigges, Christian and Lahner, Nina and Susok, Laura and Guenther, Claudia and Zeidler, Gabriele and Pfeiffer, Christiane and Worm, Margitta and Karrer, Sigrid and Aberer, Elisabeth and Bretterklieber, Agnes and Genth, Ekkehard and Simon, Jan C. and Distler, Joerg H. W. and Hein, Ruediger and Schneider, Matthias and Seitz, Cornelia S. and Herink, Claudia and Steinbrink, Kerstin and Sardy, Miklos and Varga, Rita and Mensing, Hartwig and Mensing, Christian and Lehmann, Percy and Neeck, Gunther and Fiehn, Christoph and Weber, Manfred and Goebeler, Matthias and Burkhardt, Harald and Buslau, Michael and Ahmadi-Simab, Keihan and Himsel, Andrea and Juche, Aaron and Koetter, Ina and Kuhn, Annegret and Sticherling, Michael and Hellmich, Martin and Kuhr, Kathrin and Krieg, Thomas and Ehrchen, Jan and Sunderkoetter, Cord and Hunzelmann, Nicolas (2016) Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients. JOURNAL OF RHEUMATOLOGY, 43 (1). pp. 66-74. ISSN 0315-162X, 1499-2752
Full text not available from this repository. (Request a copy)Abstract
Objective. Vasculopathy is a key factor in the pathophysiology of systemic sclerosis (SSc) and the main cause for Raynaud phenomenon (RP), digital ulcers (DU), and/or pulmonary arterial hypertension (PAH). It is so far unknown how patients with SSc are treated with vasoactive agents in daily practice. To determine to which extent patients with SSc were treated with different vasoactive agents, we used data from the German Network for Systemic Scleroderma registry. Methods. The data of 3248 patients with SSc were analyzed. Results. Patients were treated with vasoactive drugs in 61.1% of cases (1984/3248). Of these, 47.6% received calcium channel inhibitors, followed by 34.2% treated with angiotensin-converting enzyme (ACE) inhibitors, 21.1% treated with intravenous (IV) prostanoids, 10.1% with pentoxifylline, 8.8% with angiotensin 1 receptor antagonists (AT1RA), 8.7% with endothelin 1 receptor antagonists (ET1RA), 4.1% with phosphodiesterase type 5 (PDE5) inhibitors, and 5.3% with others. Patients with RP received vasoactive therapy in 63.3% of cases, with DU in 70.1%, and with PAH in 78.2% of cases. Logistic regression analysis revealed that patients with PAH were significantly more often treated with PDE5 inhibitors and ET1RA, and those with DU with ET1RA and IV prostanoids. In addition, 41.8% of patients were treated with ACE inhibitors and/or AT1RA. Patients registered after 2009 received significantly more often ET1RA, AT1RA, and IV prostanoids compared with patients registered prior to 2005. Conclusion. These data clearly indicate that many patients with SSc do not yet receive sufficient vasoactive therapy. Further, in recent years, a marked change of treatment regimens can be observed.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PULMONARY ARTERIAL-HYPERTENSION; ENDOTHELIN RECEPTOR ANTAGONIST; DIGITAL ULCERS; RAYNAUDS-PHENOMENON; VASCULAR COMPLICATIONS; CONTROLLED-TRIAL; GERMAN NETWORK; DOUBLE-BLIND; SCLERODERMA; MANAGEMENT; SYSTEMIC SCLEROSIS; VASOACTIVE THERAPY; REAL LIFE; GERMAN NETWORK FOR SYSTEMIC SCLERODERMA |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Dermatologie und Venerologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 01 Mar 2019 12:36 |
| Last Modified: | 11 Mar 2019 09:17 |
| URI: | https://pred.uni-regensburg.de/id/eprint/2241 |
Actions (login required)
 |
View Item |
